H.C. Wainwright analyst Raghuram Selvaraju downgraded UroGen Pharma (URGN) to Neutral from Buy without a price target The UGN-102 negative FDA panel vote means the firm now expects a rejection next month. The negative panel vote makes it difficult to envisage a timely approval of UGN-102, the analyst tells investors in a research note. H.C. Wainwright cites the “current uncertainties” for the downgrade.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN: